HEB - Hemispherx Biopharma, Inc. - Page 378
Hemispherx ATM Withdrawals Raise A Red Flag - * could be a short. I'd be a seller after this read.
BAD NEWS!!! lol
This Goldmine has BRUTAL upside potential because Ampligen will be the first Drug which could get approved for Chronic Fatigue Syndrome .
There are 4 Million CFS (Chronic Fatigue Syndrome) Patients in USA alone a treatment with Ampligen will cost between $30000-50000 means the Drug has MULTI BILLION DOLLAR POTENTIAL .
You can play the Runup to Decision if you dont like to hold trough the decision Its a win win situation from current bargain level . Heb could run to $3 before FDA decision like in 2009 .
My Target is $2-3 before Decision and $7++ after FDA approval . GLTA
MarketCap : $100 M
Cash : $38 M
Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012
Arthritis Advisory Committee Will Review Ampligen(R) for Chronic Fatigue Syndrome
PHILADELPHIA, Oct. 22, 2012 -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) today announced that the U.S. Food and Drug Administration ("FDA") has scheduled for December 20, 2012 a meeting of the Arthritis Advisory Committee ("AAC") to discuss the Ampligen(R) New Drug Application for Chronic Fatigue Syndrome ("CFS") which is currently under review by the FDA. As previously announced, the Prescription Drug User Fee Act ("PDUFA") review goal for the FDA to complete its review is February 2, 2013.